Mechanisms Involved in Focal Adhesion Signaling Regulating Tumor Anoikis Resistance

IF 4.3 2区医学 Q1 ONCOLOGY

Cancer Science Pub Date : 2025-08-05 DOI:10.1111/cas.70154

Bin Liu, Qingqing Wu, Zuodong Xuan, Zeyuan Zheng, Yifan Du, Xiuyuan Sui, Haodong Wu, Zeyi Zhang, Zhengying Zhang, Min Zhong, Yue Zhao, Huimin Sun, Chen Shao

{"title":"Mechanisms Involved in Focal Adhesion Signaling Regulating Tumor Anoikis Resistance","authors":"Bin Liu, Qingqing Wu, Zuodong Xuan, Zeyuan Zheng, Yifan Du, Xiuyuan Sui, Haodong Wu, Zeyi Zhang, Zhengying Zhang, Min Zhong, Yue Zhao, Huimin Sun, Chen Shao","doi":"10.1111/cas.70154","DOIUrl":null,"url":null,"abstract":"<p>Among the numerous malignant behaviors of tumors, metastasis plays a critical role in contributing to poor prognosis. Anoikis is a distinct form of apoptosis induced when cells detach from the extracellular matrix (ECM) or adhere to an improper ECM. It is a physiological obstacle to tumor cell metastasis. Anoikis resistance is considered to be a critical initial step in cancer cell metastasis. However, the mechanism by which tumor cells develop anoikis resistance is still unclear, in which the focal adhesion signaling pathway plays an important role. This review first outlines the composition of focal adhesion (FAs) multi-protein signaling complexes and then discusses the following three aspects: integrin expression changes of tumor cells, intracellular oxidative stress response, and FAs multi-protein signaling complex members activating downstream survival signaling pathways. The specific mechanisms of focal adhesion signaling pathways in tumor cell anoikis resistance and molecular characteristics of the anoikis resistance state are reviewed.</p>","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"116 10","pages":"2640-2648"},"PeriodicalIF":4.3000,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cas.70154","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Science","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cas.70154","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Among the numerous malignant behaviors of tumors, metastasis plays a critical role in contributing to poor prognosis. Anoikis is a distinct form of apoptosis induced when cells detach from the extracellular matrix (ECM) or adhere to an improper ECM. It is a physiological obstacle to tumor cell metastasis. Anoikis resistance is considered to be a critical initial step in cancer cell metastasis. However, the mechanism by which tumor cells develop anoikis resistance is still unclear, in which the focal adhesion signaling pathway plays an important role. This review first outlines the composition of focal adhesion (FAs) multi-protein signaling complexes and then discusses the following three aspects: integrin expression changes of tumor cells, intracellular oxidative stress response, and FAs multi-protein signaling complex members activating downstream survival signaling pathways. The specific mechanisms of focal adhesion signaling pathways in tumor cell anoikis resistance and molecular characteristics of the anoikis resistance state are reviewed.

Abstract Image

查看原文本刊更多论文

局灶黏附信号调控肿瘤耐药的机制。

在肿瘤众多的恶性行为中，转移是导致预后不良的重要因素。Anoikis是细胞脱离细胞外基质（ECM）或附着在不合适的细胞外基质上时诱导的一种独特的细胞凋亡形式。它是肿瘤细胞转移的生理障碍。Anoikis耐药被认为是癌细胞转移的关键初始步骤。然而，肿瘤细胞产生anoikis耐药的机制尚不清楚，其中局灶黏附信号通路起重要作用。本文首先概述了局灶黏附（FAs）多蛋白信号复合物的组成，然后从肿瘤细胞整合素表达变化、细胞内氧化应激反应和FAs多蛋白信号复合物成员激活下游生存信号通路三个方面进行了讨论。综述了肿瘤细胞耐药过程中黏附信号通路的具体机制和耐药状态的分子特征。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Science 医学-肿瘤学

自引率

3.50%

发文量

406

审稿时长

2 months

期刊介绍： Cancer Science (formerly Japanese Journal of Cancer Research) is a monthly publication of the Japanese Cancer Association. First published in 1907, the Journal continues to publish original articles, editorials, and letters to the editor, describing original research in the fields of basic, translational and clinical cancer research. The Journal also accepts reports and case reports. Cancer Science aims to present highly significant and timely findings that have a significant clinical impact on oncologists or that may alter the disease concept of a tumor. The Journal will not publish case reports that describe a rare tumor or condition without new findings to be added to previous reports; combination of different tumors without new suggestive findings for oncological research; remarkable effect of already known treatments without suggestive data to explain the exceptional result. Review articles may also be published.